Aesthetics360

Built AI native rather than retrofitted, by the company's own account, with a multi agent architecture in which every component is model output: Scribe for capture, Notes for documentation, Plan for treatment planning, and an analytics layer above them. No services business or legacy platform underneath.

Two things push this down. A360 Notes is marketed as producing chart ready output WITHOUT MANUAL EDITS OR POST VISIT WORK, which sells the absence of review as a benefit rather than describing a review step, and no confidence threshold, acceptance rate or clinician sign off gate was located. Separately A360 Plan delivers AI powered TREATMENT RECOMMENDATIONS and personalised care plans, which is clinical recommendation rather than documentation, with no oversight model described for it either. In elective medicine, where the recommended treatment is also the thing being sold, an unreviewed recommendation engine deserves more scrutiny than it would elsewhere, not less.

The pipeline is described with unusual mechanical specificity for this category, naming medical named entity recognition, intent detection and contextual classification as distinct stages, and the domain tuning claim is illustrated concretely rather than asserted: the phrase eleven lines can mean facial anatomy or units of product depending on context, an ambiguity a general transcription model would resolve wrongly. That is a real demonstration of domain understanding. Graded C nonetheless because nothing is measured: no accuracy figure, model card, named models or evaluation methodology was located, which is the same call applied to DeepCura for a comparably detailed architecture with no numbers behind it.

No study, controlled evaluation, accuracy benchmark, third party rating, named customer or deployment count was located. Available testimony is brief and unattributed to a named practice. Claims of significant reductions in documentation time and more consistent notes carry no denominator or method.

One genuinely strong architectural claim, held against one structural tension. The strong part: ON DEVICE REDACTION and encryption AT CAPTURE, meaning identifiers are stripped before transmission rather than after arrival, which is engineered privacy of the kind this index credits in voize and Veradigm. The tension: the platform's stated value depends on analysing EVERY TRANSCRIPT for patterns, opportunities and performance feedback, so retention and reuse of conversation content is not incidental to this product, it is the business model. Those are not contradictory, since identifiers can be redacted while content is kept, but a buyer should understand that conversations are retained and mined by design. No retention schedule or training use statement was located.

HIPAA compliance is claimed, and the product is described as designed for regulated environments with workflows aligned to HIPAA, PHI and audit requirements. One inconsistency worth noting: some materials say fully HIPAA compliant while others describe HIPAA ALIGNED infrastructure, and aligned is a materially weaker word that this index tracks elsewhere as a near attestation. Business associate agreement terms are not published.

Not assessed. Enterprise grade is a marketing phrase rather than a standard, and no named or dated attestation and no trust centre was located.

Not a regulated medical device and none claimed. Flag rather than grade: A360 Plan generates treatment recommendations and long term care plans, which is advising on care rather than recording it, and sits closer to regulated decision support than documentation does.

Graded on disclosed design, not on any allegation, and the grade rests on what the vendor markets rather than anything uncovered. A360 Scribe is stated to capture revenue signals alongside clinical content, specifically patient motivations, timing cues, decision language, financial framing and pricing discussion. A360 Plan is described as capturing every REVENUE RELEVANT SIGNAL in the consultation. The platform then analyses EVERY TRANSCRIPT to surface conversion leaks, revenue, reactivation and campaign opportunities, and to give staff performance feedback that no traditional training can. Two separate concerns follow, and neither has any published governance framework, patient disclosure or fairness content behind it. First, secondary use: a patient consents to a recording for their clinical record, and the same recording drives a system optimising how to sell them further elective procedures. Second, workforce surveillance: analysing every consultation to score staff performance is employee monitoring conducted through patient conversations, the concern this index tracks elsewhere in workforce analytics. In fairness, aesthetic medicine is openly commercial, pricing genuinely is discussed in these consultations, and recording what was recommended, deferred or declined is legitimate clinical record keeping. The grade is for the undisclosed secondary use of clinical recordings, not for the specialty being commercial.

Integration is offered as a capability rather than a list: the product can run standalone or connect to EMRs and other systems through APIs, and the company maintains a dedicated proposition for EMR vendors alongside an agent exchange and studio. No named electronic record integration, architecture or write back mechanism was verified in this pass, so depth cannot be assessed.

Partial. On device redaction and encryption at capture is a real and unusual deployment property, meaningfully stronger than server side redaction because identifiers never leave the device unprotected. Against that, no hosting region, residency option or sub processor detail was located, and the analytics layer implies substantial cloud side retention.

No published rate card, tier structure or pricing model. Enterprise buyers are directed to a consultative assessment. Given the platform spans documentation, treatment planning, analytics and marketing activation, a buyer cannot currently determine which components are licensed together or separately.

Opens a segment nothing else in this index reaches: elective and largely cash pay aesthetic medicine, covering aesthetics, plastics and venous care, sold to medical spas as well as larger clinics, hospitals and networks. That setting has genuinely different documentation needs from insurance funded care, since the note supports consent, expectation setting and product traceability rather than a claim. The product reflects that, documenting what was recommended, deferred or declined and recording expectation setting in real time to reduce downstream misalignment, which is a defensible medico legal purpose in a specialty with high patient dissatisfaction risk. No specialty count or language coverage published.